Semaglutide vs CJC-1295
A comprehensive, data-driven comparison of Semaglutide (Ozempic) and CJC-1295 (Modified GRF 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Semaglutide Ozempic, Wegovy | CJC-1295 Modified GRF 1-29, DAC:GRF |
|---|---|---|
| FDA Status | FDA Approved | Category 2 (pending reclassification) |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Type 2 diabetes, chronic weight management, and MASH | Growth hormone optimization and anti-aging |
| Weight Loss % | 15% | N/A |
| Monthly Cost | $1,000 - $1,400/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2.4mg weekly (Wegovy dose) | 1-2mg twice weekly (with DAC) |
| Frequency | Weekly | Twice weekly |
| Mechanism | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Semaglutide is FDA-approved, while CJC-1295 is currently category 2 (pending reclassification).
- 2Semaglutide has clinical weight loss data (15%), while CJC-1295 is not primarily indicated for weight loss.
- 3CJC-1295 is generally more affordable ($35 - $70/mo) compared to Semaglutide ($1,000 - $1,400/mo).
- 4Semaglutide is dosed weekly, while CJC-1295 is twice weekly.
- 5Semaglutide has high-quality evidence, while CJC-1295 has emerging-quality evidence.
- 6They belong to different categories: Semaglutide (Weight Loss) vs CJC-1295 (Growth Hormone).
Which Is Better For...
Semaglutide
Those seeking an FDA-approved treatment with established safety data
CJC-1295
More budget-friendly option with lower monthly costs
Semaglutide
More convenient dosing schedule (weekly)
CJC-1295
Fewer commonly reported side effects
Semaglutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. They differ in FDA approval status, efficacy data, and cost.
Semaglutide has demonstrated 15% average weight loss in clinical trials. CJC-1295 is not primarily used for weight loss.
Semaglutide typically costs $1,000 - $1,400/mo, while CJC-1295 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Semaglutide is FDA-approved. CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metab...
View Full Semaglutide GuideCJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Semaglutide and CJC-1295 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.